Brief: Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer
16/03/2026 11:40
March 16 (Reuters) - CytomX Therapeutics Inc CTMX.O: CYTOMX’S VARSETATUG MASETECAN (EPCAM PROBODY® ADC) CONTINUES TO DEMONSTRATE POSITIVE DATA SUPPORTING POTENTIAL AS A NEW TREATMENT OPTION IN LATE-LINE COLORECTAL CANCER CYTOMX THERAPEUTICS INC - PHASE 1 STUDY WITH BEVACIZUMAB INITIATED; PHASE 1B/2 CHEMOTHERAPY COMBINATION STUDY TO START BY END 2026 Source text: ID:nGNX97vc6b Further company coverage: CTMX.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway